Compare Schwab US Large Cap Growth ETF (SCHG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs Viatris Inc — how do they compare? Schwab US Large Cap Growth ETF trades at $34.27, while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Schwab US Large Cap Growth ETF pays none, and Viatris Inc is trading nearer its 52-week high, Schwab US Large Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| SCHG | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $35.30 | $17.39 |
52-Week Low | $28.10 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $34.15, down 0.09% on the day, with a neutral technical signal. The ETF offers concentrated exposure to U.S. large-cap growth stocks, particularly in technology and AI-driven sectors, with a low 0.04% expense ratio. Recent institutional buying includes a 7.3% position increase by Alpha Zero LLC (Defense World, July 21, 2026).
Outlook remains mixed; strong fundamentals and AI growth potential support long-term gains, but high concentration in top holdings and elevated valuations near 32x P/E pose risks. Market sentiment is divided between bullish growth prospects and concerns over reliance on mega-cap performance.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
